Vera Therapeutics (VERA) Liabilities and Shareholders Equity (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $621.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 1.9% year-over-year to $621.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (up 20.71% YoY), and the FY2025 full-year result was $734.7 million, up 12.06% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $621.7 million, down from $734.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $734.7 million in Q4 2025 and bottomed at $131.4 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $368.6 million (2024), against an average of $366.8 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity surged 273.51%; it then grew 1.9% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $131.4 million in 2022, then soared by 33.56% to $175.5 million in 2023, then soared by 273.51% to $655.7 million in 2024, then gained by 12.06% to $734.7 million in 2025, then declined by 15.38% to $621.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $621.7 million (Q1 2026), $734.7 million (Q4 2025), and $517.5 million (Q3 2025), per Business Quant data.

Peer Comparison